Background:Non-Alcoholic Fatty Liver Disease (NAFLD) is a common hepatic manifestation of metabolic dysfunction, particularly among obese individuals. Systemic inflammation plays a pivotal role in the progression of NAFLD. Inflammatory biomarkers such as Interleukin-6 (IL-6), C-Reactive Protein (CRP), and Tumor Necrosis Factor-alpha (TNF-α) have been identified as potential indicators of hepatic and metabolic alterations. This study aims to evaluate and compare levels of inflammatory biomarkers in obese individuals with and without NAFLD, highlighting the intersection of gastroenterology and endocrinology. Materials and Methods:A cross-sectional analytical study was conducted on 100 obese individuals (BMI ≥30 kg/m²) aged 25–60 years. Participants were divided into two groups: Group A (n=50) with ultrasonographically confirmed NAFLD and Group B (n=50) without NAFLD. Fasting blood samples were collected for analysis of IL-6, CRP, and TNF-α levels using ELISA. Clinical parameters including BMI, waist circumference, fasting blood glucose, lipid profile, and liver function tests were also assessed. Statistical analysis was performed using SPSS version 26.0 with p<0.05 considered statistically significant. Results:Mean IL-6 levels were significantly higher in Group A (8.42 ± 2.3 pg/mL) compared to Group B (4.15 ± 1.1 pg/mL; p<0.001). CRP levels in Group A averaged 6.88 ± 1.9 mg/L versus 3.14 ± 1.2 mg/L in Group B (p<0.01). Similarly, TNF-α levels were elevated in Group A (11.53 ± 2.6 pg/mL) compared to Group B (6.75 ± 1.7 pg/mL; p<0.001). A positive correlation was observed between inflammatory biomarkers and liver enzyme levels (ALT and AST) in the NAFLD group. Conclusion:Obese individuals with NAFLD exhibit significantly elevated inflammatory markers compared to those without hepatic steatosis. These findings support the hypothesis that low-grade chronic inflammation serves as a pathogenic link between metabolic dysfunction and hepatic injury. Early identification and targeted anti-inflammatory interventions may help in halting NAFLD progression and associated endocrine complications.